What is Lyndra Therapeutics?
Founded in 2015 and headquartered in Watertown, Massachusetts, Lyndra Therapeutics is at the forefront of pharmaceutical manufacturing, specializing in advanced drug delivery solutions. The company is recognized for its pioneering work in developing long-acting oral therapies, aiming to revolutionize patient adherence and treatment efficacy. Its technology platform is designed to enable weekly or even monthly dosing, a significant advancement over traditional daily regimens. This innovation positions Lyndra Therapeutics as a key player in addressing unmet medical needs and improving patient outcomes across various therapeutic areas.
How much funding has Lyndra Therapeutics raised?
Lyndra Therapeutics has raised a total of $239.5M across 4 funding rounds:
Series A
$23M
Series B
$55M
Series C
$60.5M
Series E
$101M
Series A (2018): $23M with participation from Polaris Partners
Series B (2019): $55M, investors not publicly disclosed
Series C (2021): $60.5M supported by Polaris Partners, Invus, Limitless Ventures, Yipinhong Pharmaceutical Co., and AIG Global Investment Group
Series E (2023): $101M featuring Polaris Partners, Sun Pharma, and Sarissa Capital Acquisition
Key Investors in Lyndra Therapeutics
Polaris Partners
Polaris Partners is a venture capital firm that specializes in backing transformational companies in the biotech and healthcare sectors. With over two decades of experience, they partner with entrepreneurs to create successful business solutions, providing coaching, advice, and resources for growth.
Sun Pharma
Sun Pharma is a specialty generic pharmaceutical company that manufactures and distributes pharmaceutical formulations and active pharmaceutical ingredients. It is headquartered in Mumbai, India.
Invus
Invus Group is an investment firm specializing in financial advice, investment services, and consulting services. The company was founded in 1985 and is headquartered in New York City, New York.
What's next for Lyndra Therapeutics?
With the recent major strategic investment, Lyndra Therapeutics is poised for accelerated growth and the scaling of its operations. The substantial capital infusion, part of its $239.5M in total funding, will likely be directed towards advancing its pipeline of long-acting therapies through clinical trials, expanding manufacturing capabilities, and potentially pursuing strategic partnerships or commercialization efforts. The company's focus on innovative drug delivery systems suggests a trajectory aimed at capturing significant market share in the pharmaceutical industry, particularly in areas where patient compliance is a critical challenge. This funding round signals strong investor confidence in Lyndra's technology and its potential to disrupt traditional pharmaceutical models.
See full Lyndra Therapeutics company page
